Smallpox vaccine delivered to national stockpile

One million doses of the smallpox vaccine IMVAMUNE have been delivered to the U.S. Strategic National Stockpile for use in the event of a smallpox bioterrorism attack on the U.S.

The first vaccine successfully developed under Project BioShield, IMVAMUNE was clinically developed and manufactured under contracts with the Biomedical Advanced Research and Development Authority as well as the National Institutes of Health.

Under the BARDA contract, 20 million doses of IMVAMUNE will be delivered to the U.S. Strategic National Stockpile by Bavarian Nordic, with an option for an additional 60 million doses.

"We are gratified that the U.S. Government has added our vaccine to the Strategic National Stockpile," Anders Hedegaard, Bavarian Nordic's president and CEO, said. "This represents a significant milestone for our company, our first major sale to the U.S. Our partnership with NIH, BARDA and HHS over the recent years is a case study in successful public-private partnerships to combat bioterrorism. We look forward to continuing that partnership through other contracts with the U.S government."

Unlike conventional smallpox vaccines, IMVAMUNE, a non-replicating strain of vaccinia virus, does not carry the ability to replicate in human cells, eliminating any risk of accidental infection.

Stockpiled smallpox vaccines are currently based on a replicating form of the vaccinia virus and are considered inappropriate for as much as 25 percent of the population that could be immunocompromised or have other medical conditions that contraindicate a replicating viral vaccine.

Organizations in this story

National Institutes of Health 9000 Rockville Pike Bethesda, MD 20892

Get notified the next time we write about National Institutes of Health!